Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2013 2
2014 1
2015 7
2016 1
2017 4
2018 2
2019 2
2020 1
2021 4
2022 8
2023 11
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Tirzepatide Once Weekly for the Treatment of Obesity.
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Jastreboff AM, et al. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. N Engl J Med. 2022. PMID: 35658024 Clinical Trial.
Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
Yang W, Dong X, Li Q, Cheng Z, Yuan G, Liu M, Xiao J, Gu S, Niemoeller E, Chen L, Ping L, Souhami E; LixiLan-O-AP trial investigators. Yang W, et al. Among authors: cheng z. Diabetes Obes Metab. 2022 Aug;24(8):1522-1533. doi: 10.1111/dom.14722. Epub 2022 May 12. Diabetes Obes Metab. 2022. PMID: 35441412 Clinical Trial.
Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
Zhang B, Cheng Z, Chen J, Zhang X, Liu D, Jiang H, Ma G, Wang X, Gan S, Sun J, Jin P, Yi J, Shi B, Ma J, Ye S, Wang G, Ji L, Gu X, Yu T, An P, Deng H, Li H, Li L, Ma Q, Qian L, Yang W. Zhang B, et al. Among authors: cheng z. Diabetes Care. 2024 Jan 1;47(1):160-168. doi: 10.2337/dc23-1287. Diabetes Care. 2024. PMID: 37943529 Free PMC article. Clinical Trial.
Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study.
Gu J, Zhang H, Xue Q, Wang L, Cheng Z, Zhang Y, Li Q, Yuan L, Li Y, Dong J, Huo Y, Tang X, Hu L, Wang X, Hua F, Shen L, Cheng J, Zhou H, Xu Y, Yang T, Wang C, Xu J, Shen J, Zhang Y, Zhang X, Hong D, Guan X, Xiao X, Wang G, Liu Y, Fu L, Chen J, Cheng X, Ding Y, Liu L, Yao Q, Zhang X, Li L, Zhang P, Deng C, Jiang C, You L, Wang K, Zhang S, Xiao J, Liu W, Du X, Shang X, Pan T, Lei C, Guo S, Zhang Z. Gu J, et al. Among authors: cheng z. J Orthop Translat. 2022 Oct 29;38:117-125. doi: 10.1016/j.jot.2022.06.007. eCollection 2023 Jan. J Orthop Translat. 2022. PMID: 36381249 Free PMC article.
Efficacy of noiiglutide injection on body weight in obese Chinese adults without diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 2 trial.
Li Y, Cheng Z, Lu W, Li P, Jiang H, Yang J, Xu J, Zhang C, Zhang L, Wang Y, Bian F, Guo W, Yu X, Chen X, Zhao D, Feng B, Qu S, Qin J, Zhang Y, Wang L, Cheng H, Mu Y. Li Y, et al. Among authors: cheng z. Diabetes Obes Metab. 2024 Mar;26(3):1057-1068. doi: 10.1111/dom.15407. Epub 2023 Dec 17. Diabetes Obes Metab. 2024. PMID: 38105342 Clinical Trial.
43 results